Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies

Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies

Background and objectivesSince the results of previous observational studies on the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and pancreatic cancer were still controversial and inconsistent, we performed a systematic evaluation and meta-analysis of cohort...

Full description

Bibliographic Details
Main Authors:	Yi Zhang, Ben-Gang Zhou, Ji-Dong Zhan, Bin-Bin Du
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Series:	Frontiers in Oncology
Subjects:	non-alcoholic fatty liver disease metabolic dysfunction-associated steatotic liver disease pancreatic cancer cohort studies meta-analysis systematic review
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1366195/full

Similar Items

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
by: Gi-Ae Kim, et al.
Published: (2023-10-01)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
by: Katharina Staufer, et al.
Published: (2023-07-01)

Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma
by: Yumin Wang, et al.
Published: (2024-01-01)

Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
by: Byeong Geun Song, et al.
Published: (2024-03-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
by: Wayne Eskridge, et al.
Published: (2023-09-01)

Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
by: Tsubasa Tsutsumi, et al.
Published: (2024-04-01)

Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Avneet Singh, et al.
Published: (2024-02-01)

Mitochondrial Dysfunction-Associated Mechanisms in the Development of Chronic Liver Diseases
by: Madan Kumar Arumugam, et al.
Published: (2023-10-01)

Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort studyResearch in context
by: Joon Ho Moon, et al.
Published: (2023-11-01)

Deciphering the liver enigma: distinguishing drug-induced liver injury and metabolic dysfunction-associated steatotic liver disease—a comprehensive narrative review
by: Miren García-Cortés, et al.
Published: (2023-12-01)

What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside
by: Pojsakorn Danpanichkul, et al.
Published: (2024-01-01)

Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study
by: Michihiro Iwaki, et al.
Published: (2024-04-01)

Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver Disease
by: Zehra N. Kocas-Kilicarslan, et al.
Published: (2024-01-01)

Autophagy, Ferroptosis, Apoptosis and Pyroptosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Shuangshuang Zhao, et al.
Published: (2024-01-01)

Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
by: Hidekatsu Yanai, et al.
Published: (2023-10-01)

Severity and Remission of Metabolic Dysfunction–Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence
by: Jingli Gao, et al.
Published: (2024-03-01)

Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors
by: Yoshihisa Takahashi, et al.
Published: (2023-10-01)

The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis
by: Yvonne Burmeister, et al.
Published: (2023-12-01)

Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver diseaseKey points
by: Guillaume Henin, et al.
Published: (2024-02-01)

Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic
by: Guocheng Rao, et al.
Published: (2023-11-01)

Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso)
by: Rodrigo Oliveira Moreira, et al.
Published: (2023-12-01)

Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Soyeon Shin, et al.
Published: (2023-12-01)

Low thyroid function is associated with metabolic dysfunction‐associated steatotic liver disease
by: Shuo Wang, et al.
Published: (2024-02-01)

Melatonin Prevents Alcohol- and Metabolic Dysfunction- Associated Steatotic Liver Disease by Mitigating Gut Dysbiosis, Intestinal Barrier Dysfunction, and Endotoxemia
by: Karli R. LeFort, et al.
Published: (2023-12-01)

The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque
by: Yunqian Huang, et al.
Published: (2023-11-01)

2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes
by: Amélio F. Godoy-Matos, et al.
Published: (2024-01-01)

Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
by: Koki Nagai, et al.
Published: (2023-10-01)

The Portal Venous Pulsatility Index and Main Portal Vein Diameter as Surrogate Markers for Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Metabolic-Dysfunction-Associated Steatotic Liver Disease
by: Jaejun Lee, et al.
Published: (2024-02-01)

An Optimized Strategy Based on Conventional Ultrasound for Diagnosing Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Xiongcai Feng, et al.
Published: (2023-11-01)

Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants
by: Sergio M. López Tórrez, et al.
Published: (2024-02-01)

Metabolic dysfunction-associated steatotic liver disease: ferroptosis related mechanisms and potential drugs
by: Baoqiang Zhu, et al.
Published: (2023-11-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease in a Dish: Human Precision-Cut Liver Slices as a Platform for Drug Screening and Interventions
by: Mei Li, et al.
Published: (2024-02-01)

Molecular Mechanisms of Curcumin in the Pathogenesis of Metabolic Dysfunction Associated Steatotic Liver Disease
by: Marta Guariglia, et al.
Published: (2023-12-01)

Different Associations of Coffee Consumption with the Risk of Incident Metabolic Dysfunction-Associated Steatotic Liver Disease and Advanced Liver Fibrosis
by: Jun-Hyuk Lee, et al.
Published: (2023-12-01)

Alterations of the duodenal mucosal microbiome in patients with metabolic dysfunction-associated steatotic liver disease
by: Mengting Ren, et al.
Published: (2024-04-01)

A systematic review and meta-analysis of cohort studies on the potential association between NAFLD/MAFLD and risk of incident atrial fibrillation
by: Ben‐Gang Zhou, et al.
Published: (2023-07-01)

Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation
by: Byeong Hyun Min, et al.
Published: (2024-12-01)

Phosphorylation: new star of pathogenesis and treatment in steatotic liver disease
by: Tiansu Lv, et al.
Published: (2024-02-01)

Pathophysiological Mechanisms and Clinical Associations of Non-Alcoholic Fatty Pancreas Disease
by: Pagkali A, et al.
Published: (2024-01-01)

Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
by: Joo Hyun Oh, et al.
Published: (2024-04-01)